Changes to expert opinion in the use of antirheumatic drugs before and during pregnancy five years after EULAR: points to consider
Rheumatology (Oxford)
.
2022 Nov 2;61(11):e331-e333.
doi: 10.1093/rheumatology/keac262.
Authors
Véronique Laure Ramoni
1
,
Céline Häfeli
2
,
Nathalie Costedoat-Chalumeau
3
4
,
Christina Chambers
5
,
Radboud J E M Dolhain
6
,
Marcello Govoni
7
8
,
Roger A Levy
9
,
Carina Götestam Skorpen
10
11
,
Angela Tincani
12
,
Frauke Förger
2
Affiliations
1
Medicina Generale Lodi, ASST Lodi - Ospedale Maggiore, Lodi, Italy.
2
Department of Rheumatology and Immunology, Inselspital, University Hospital and University of Berne, Freiburgstrasse, Bern, Switzerland.
3
Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP, Hôpital Cochin.
4
Centre de Recherche Épidémiologie et Biostatistiques de Sorbonne Paris Cité, Université de Paris, Paris, France.
5
Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
6
Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
7
Azienda Ospedaliero Universitaria S. Anna.
8
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
9
GlaxoSmithKline, Collegeville, PA, USA.
10
Department of Rheumatology, Ålesund Hospital, Ålesund.
11
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
12
Rheumatology and Clinical Immunology Unit, ASST-Spedali Civili and University of Brescia, Brescia, Italy.
PMID:
35587743
DOI:
10.1093/rheumatology/keac262
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Expert Testimony
Female
Humans
Pregnancy
Substances
Antirheumatic Agents